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Chapter I. General overview 
 
1.1. Background and purposes 
Chronic kidney disease, or chronic renal failure (CKD or CRF), with impaired 
renal function necessitates dialysis or kidney transplantation. Late stages of chronic 
kidney disease leads to a numerous of complications such as uremia, oxidative stress, 
anemia, fluid overload which cause a delay in wound healing. Mesenchymal stem cells 
(MSCs) are considered to be a candidate for wound healing because of the ability to 
recruit many types of cells. However, it is still unclear whether the CRF-derived MSCs 
(CRF-AT-MSCs) have the same function in wound healing as healthy donor-derived 
MSCs (nAT-MSCs). The present study aimed to investigate the effect of uremic toxins, 
commonly accumulate in CRF patients, to wound healing function of MSCs. Furthermore, 
I aimed to characterized and analyzed the function of MSCs from adipose tissue of 
healthy donors and CRF patients in wound healing. 
 
1.2. Material and methods 
Firstly, the MSCs isolated from adipose tissues of healthy donors (nAT-MSCs) 
were analyzed under the treatment of uremic toxins in normoxic and hypoxic conditions. 
p-cresol, hippuric acid, and indoxyl sulfate were used as the uremic toxins. The 
expression of reactive oxygen species (ROS) were measured by staining AT-MSCs with 
2',7'-dichlorodihydrofluorescein diacetate (H2-DCFDA). The gene and protein levels 
were performed by quantitative reverse transcription polymerase (qRT-PCR) and 
Western blot. Then, AT-MSCs from non-diabetic CKD patients stages 3-4 (CKD-AT-
MSCs) were characterized by morphology, growth curve, fluorescence-activated cell 
sorting (FACS) and differentiation assay. Inhibition of ROS was performed by treatment 
with N-acetyl-L-cysteine (NAC) and inhibition of prolyl-hydroxylase domain protein 2 
(PHD-2) was carried out by treatment with IOX2 and small hairpin RNA target PHD-2 
(shPHD-2). The flap mouse model was used as in vivo wound healing assays. 
 
1.3. Results 
In the present study, I found that uremic toxins induced elevated ROS expression 
in nAT-MSCs, resulting in the reduced expression of HIF-1 under hypoxic conditions 
and the impaired wound healing function. Consistent with the uremic-treated AT-MSCs, 
there was a definite imbalance of redox state and high expression of ROS in CKD-AT-
MSCs. Of note, the elevated ROS expression in CKD-AT-MSCs induced prolyl 
hydroxylase 2 (PHD-2) expression which caused the inhibition of HIF-1 expression. In 
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addition, a transplantation study clearly revealed that nAT-MSCs promoted the 
recruitment of inflammatory cells and recovery from ischemia in the mouse flap model, 
whereas CKD-AT-MSCs had defective functions and the wound healing process was 
delayed.  
 
1.4. Conclusion 
My study provides a tight relationship between the increase of intracellular ROS 
levels and the impaired activation of HIF-1and wound healing function of AT-MSCs in 
both uremic toxin-treated condition or CKD patients. In particular, we show that the 
expression of prolyl hydroxylase domain 2 (PHD2) is selectively increased in CKD-AT-
MSCs and its inhibition successfully restores HIF-1 activation and the wound healing 
ability in these cells. These results indicate that MSCs from CKD patients need to modify 
the characteristics before applying for the clinical setting.   
 
1.5. Abbreviations 
CRF   chronic renal failure 
CKD   chronic kidney disease 
GFR   glomerular filtration rate 
ESKD   end-stage kidney disease 
AT-MSCs  adipose tissue-derived mesenchymal stem cells  
nAT-MSCs  AT-MSCs from healthy donors 
CRF-AT-MSCs AT-MSCs from CRF patients 
HA   hippuric acid 
IS   indoxyl sulfate 
NAC   N-acetyl-L-cysteine  
IOX2   N-[[1,2-dihydro-4-hydroxy-2-oxo-1-(phenylmethyl)-3        
                 quinolinyl] carbonyl]-glycine 
CM-H2DCFDA 2',7'-dichlorodihydrofluorescein diacetate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
PHD-2   prolyl hydroxylase domain protein 1 
ROS   reactive oxygen species 
HIF-1  hypoxic inductive factor 1  
SOD1   superoxide dismutase 1 
GPX1   glutathione peroxidase 1 
VEGF   vascular endothelial growth factor 
SDF-1   stromal cell-derived factor 1 
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Chapter II. Uremic toxins affects the imbalance of redox state and overexpression 
of prolyl hydroxylase 2 in AT-MSCs involved in wound healing 
 
2.1. Introduction  
2.1.1. The accumulation of uremic toxins in chronic kidney disease patients 
Kidney plays the vital role in the body to filter the extra water and toxins from 
the blood by the glomerular filter and balance the body fluids. Chronic kidney 
disease (CKD) involves the progressive loss of renal function over a period of 
months or years and results in elevated levels of waste materials, such as urea, 
creatinine, potassium, in the body, as well as changes in the hormone levels that 
control blood pressure and the uptake of calcium [1]. The extension of CKD stages 
leads to the total loss of kidney function and eventually results in mortality [1]. 
According to the progression of kidney damage, CKD is classified into 5 progressive 
stages, indicative of organ damage level and reduced glomerular filtration rate 
(GFR) [1]. In stage 1, when the kidney has normal function but urine findings or 
structural abnormalities which point to kidney disease are observed, the GFR is still 
high, over 90 ml/min. The GFR reduces mildly in stage 2, from 60 to 89 ml/min with 
the mild reduction of kidney function. The kidney function moderately reduced at 
stage 3, with GFR from 30 to 59 ml/min. Stage 4 is identified when GFR reduces, 
from 15 to 29 ml/min which is associated with severely reduced kidney function. 
Stage 5 is considered to be end-stage kidney disease (ESKD), with the GFR less 
than 15 ml/min and the patients are usually on dialysis [1].  
In general, the healthy glomerular filter has the ability to keep the molecules with 
weights up to 58 kDa [2]. The proteins and small molecules of body waste products 
were excreted to urine. In renal failure, the glomerular filtration is reduced or the 
abnormalities in renal metabolism cause the accumulation of a variety compounds 
which are called uremic toxins [2]. Classically, uremic toxins are divided into three 
types of molecules [3,4]. The small water-soluble compounds have the molecular 
weight less than 500 Da and can easily remove by dialysis strategy [3,4]. The 
protein-bound compounds also have the molecular weight less than 500 Da and 
have the capacity to bind to proteins which are difficult to remove by dialysis [3,4]. 
The last group is the middle molecular weight molecules which have the molecular 
weight more than 500 Da [3,4]. The accumulation of uremic toxins is associated with 
the progression of CRF and causes the dysfunction of multiple of cell types and 
organs, thus negatively affects many biological processes [5].  
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2.1.2. Delay wound healing in CRF patients 
Functional renal failure causes the delay of wound healing in CRF patients 
because of the consequent complications [6-11]. The accumulation of uremic toxins 
impairs the function of many types of cells contributing to wound healing process [6-
8]. Some uremic toxins are known to increase production of the reactive oxygen 
species level (ROS), a hallmark of uremic syndrome [6-8]. The elevated and 
sustained ROS causes the sustained pro-inflammatory cytokine secretion, induction 
of matrix metalloproteases, impairment of dermal fibroblast and keratinocyte 
function [9,10]. ROS is also known to be involved in the regulation of hypoxic 
inducible factors which play the central role in wound healing [10]. In ESKD patients 
who have the severe retention of uremic toxins that leads to uremia, there is the 
abnormal level of zinc which can promote the wound healing through the auto-
debridement and keratinocyte migration [11]. In addition, another complication of 
CRF such as anemia, which is associated with poor tissue oxygenation, and fluid 
overloading, which is known as the cause of extensive edema in the lower 
extremities, are considered as another barrier to wound-healing [11].  
Wound healing process consists of four integrated and overlapping phases, 
hemostasis, inflammation, proliferation and tissue remodeling [12]. Each phase 
requires the combined activity of growth factors and extracellular matrix proteins, 
involving with many types of cells such as inflammatory, endothelial, epithelial, and 
fibroblast cells [12]. These phases of healing can be failed to progress by many 
factors that cause the impaired healing of wound and ulcers [13]. Most ulcers are 
associated with ischemia, pressure or metabolic disease as diabetes mellitus, 
kidney disease [13]. The significant increase number of patients with impaired 
wound has precipitated the study of the underlying regeneration in wound healing 
and new therapies for chronic wounds [13]. 
 
2.1.3. Stem cell therapy for wound healing delay complication 
Up to now, many new therapies for chronic wounds have been being assessed 
in preclinical and clinical studies [14]. Among them, stem cell therapy is considered 
as a promising approach for tissue regeneration [15]. However, no stem cell-based 
therapy has yet gained the approval for the treatment of impaired wound because 
of many barriers, including the potential risk of immunogenicity and tumorigenicity. 
The challenge to identify the appropriate stem cell populations for wound therapy 
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would be necessary to protect and improve the regenerative ability of transplanted 
stem cells in the wound environments [15,16]. 
Mesenchymal stem cells (MSCs) are defined as the multipotent progenitor cells 
that can be expanded in vitro and have the potential to differentiate into the 
mesoderm cell linages [17]. MSCs were first isolated from bone marrow therefore, 
the bone marrow-derived MSCs (BM-MSCs) have been extensively studied [17]. 
However, many other sources of MSCs have been reported such as umbilical cord 
blood, dental pulp, adipose tissues… and it is shown that compared to bone marrow, 
adipose tissue is an abundant source of MSCs from which the isolation of MSCs is 
easier, safer and larger amounts of MSCs can be obtained [18,19]. Adipose tissue-
derived MSCs (AT-MSCs) are reported to be more genetically and morphologically 
stable with a lower senescence, higher proliferative capacity and differentiation 
potential in a long-term culture. In clinical application, AT-MSCs are as effective as 
BM-MSCs, and in some cases maybe more effective than BM-MSCs [18,19]. The 
application of MSCs in stem cell therapy has been attracted many studies because 
of the multipotent to differentiate to a variety of cell linages, the immunomodulatory 
properties, the safety of usage and lack of ethical issues [20,21].  
In wound healing process, MSCs serve a keystone role in recruitment of many 
other cells in the body to the wound site [22]. MSCs are known to secrete a mixture 
of growth factors and matrix proteins which are essential for wound healing [23]. 
Therefore, MSCs are considered to be a promising therapeutic candidate to 
enhance poor wound healing caused by metabolic disease [22,23]. 
 
2.1.4. Effects of uremic toxins and CRF on mesenchymal stem cells 
characteristics and functions 
Transplantation of MSCs into rat models of CRF resulted in the improvement of 
renal function [24-26] which suggest that MSCs can be helpful for the treatment 
strategy of kidney failure. However, several reports suggested that uremic toxins, 
which are commonly retained in CRF cases, cause the damage of stem cells [27,28]. 
Treatment with uremic toxins at high concentration causes the negative effect on 
bone marrow-derived MSCs proliferation and paracrine activity in vitro [27]. Indoxyl 
sulfate, a protein-bound uremic toxin, causes the impairment of proliferation and 
induces the senescence at high concentration [28]. However, up to now, the effects 
of uremic toxins on the function of MSCs, especially in wound healing process, have 
not been well clarified yet.  
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Klinkhammer et al. reported that transplantation of bone marrow (BM)-derived 
MSCs prepared from healthy rat can help to accelerate the healing of glomerular 
lesions whereas those from CKD rat failed to exhibit such activity [29]. Roemeling-
van et al. reported that MSCs derived from adipose tissues (AT-MSCs) of human 
CRF patients showed no differences in differentiation capacity and stability than 
those from healthy donors, hinting at autologous use of these cells in CRF therapy 
[30]. However, Yamanaka et al. reported that adipose-derived MSCs from patients 
with end-stage kidney disease (ESKD), who have suffered long-term uremia, exhibit 
downregulation of hypoxic response factors and poor angiogenesis activation [31]. 
Given that availability of AT-MSCs are superior to other stem cell sources, functional 
evaluation of patient-derived AT-MSCs is important for autologous cell therapy.    
 
2.1.5. Hypoxic condition, a common condition in wound healing 
Hypoxic condition, which can cause physiological and pathological responses 
in cells, plays an important role in many biological processes [32]. Hypoxic condition 
is one of the micro-environmental conditions in tissue injury and wound healing. The 
initial tissue injury causes blood vessel damage and leads to acute hypoxia 
microenvironment at the wound site [32]. Then, the increased oxygen consumption 
by infiltrated inflammatory and stromal cells decreases the tissue oxygen tension 
which leads to chronic hypoxia [32]. Wound healing requires the combined activities 
of a variety of cells within the injured areas, and the adaption to hypoxic 
microenvironments of these cells, including inflammatory cells, keratinocytes, 
endothelial cells, and mesenchymal stem cells, is necessary to exert wound healing 
activities [32].                 
Hypoxic stimuli result in the stabilization of a master transcription factor, 
hypoxia-inducible factor-1 (HIF-1 which regulates the expression of a number of 
genes related to wound healing [33]. Several studies have shown that the hypoxia-
induced activation of HIF-1is attenuated in CRF-derived MSCs, although the 
underlying molecular mechanisms have not been fully elucidated [31,34].  
Traditionally, HIF-1 is known to be regulated by oxygen-dependent 
hydroxylase enzymes such as prolyl hydroxylase domain proteins (PHDs) [35-37]. 
PHDs is a subfamily of dioxygenases that uses oxygen and 2-oxoglutarate as co-
substrates, and iron and ascorbate as cofactors [36]. There are three main PHD 
isoforms, PHD1, PHD2, and PHD3 (also termed EGLN2, EGLN2, and EGLN3, 
respectively) which share the homologous sequence in the C-terminal catalytic 
domains while the function of N-terminal is not yet identified, and have the specific 
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expression patterns [36]. PHD2 is expressed in most tissues whereas PHD1 is 
present mainly in testes, and few in brain, kidney, heart, and liver; PHD3 is mostly 
expressed in heart [36]. In the presence of oxygen, PHDs hydroxylate HIF- 
subunits, then hydroxylated HIF-a are recognized by the von Hoppel-landau (VHL) 
protein of the E3 ubiquitin ligase complex and degraded by the polyubiquitination-
proteasomal system [36,37]. When intracellular oxygen concentration is reduced, 
non-hydroxylated HIF- subunits accumulate and heterodimerize with HIF-1 
subunit to form the transcription factors in the nucleus and regulates the expression 
of many target genes which take important roles in wound healing [36,37].  
In addition, recently, many pathways have been reported to be involved in the 
stability of HIF-1such as PI3K/Akt, MAPK, mTOR, ROS pathways [38-40]. The 
electron transport chain performs an essential function in the stabilization of HIF-1, 
suggesting that ROS are involved in the regulation of HIF-1[38-40]. However, the 
role of ROS in the regulation of HIF-1 is controversial: ROS have been reported to 
stabilize HIF-1; and high level ROS expression has been shown to lead to the 
degradation of HIF-1 in the hypoxic conditions [38-40]. Because the accumulation 
of ROS is a hallmark of CRF, understanding the role of ROS in the regulation of HIF-
1 is important for the use of CKD-AT-MSCs in regenerative medicine.  

In the present study, I aimed to analyze the the effects of uremic toxin and CKD on 
the functions of AT-MSCs in wound healing. In particular, with the central role in wound 
healing process, hypoxic stimuli were considered as the important condition of the AT-
MSCs characteristics in this study.    
 
2.2. Materials and methods 
2.2.1. The isolation and culture of adipose tissue-derived mesenchymal stem 
cells (AT-MSCs)  
 The studies are conducted according to the amended Declaration of Helsinki. All 
human cell experiments were approved by the ethics committee of the University of 
Tsukuba. Human adipose tissues were obtained from non-diabetic stage 3-4 CKD 
patients (n=5, creatinine level=1.71±0.3, GFR=45.5±9.5 ml/min per 1.73m2, male, 
age=74 ± 8 years) and healthy donors who have no diabetic and normal renal 
function (n=5, creatinine level<1, GFR=95.5±5.5 ml/min per 1.73m2, male, age=75 
± 8 years) from the Department of Cardiovascular Surgery, University of Tsukuba 
Hospital, Tsukuba, Japan. Mesenchymal stem cells were isolated from adipose 
tissues according to a previously described method [41].  
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Briefly, the adipose tissues were cut into small pieces and incubated in 
phosphate buffer saline (PBS) containing 0.1% collagenase (Invitrogen, CA) in an 
hour. The digested tissues were then separated by centrifugation and the cell pellets 
were re-suspended in culture medium, Iscove’s Modified Dulbecco Medium (IMDM, 
Invitrogen), supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Invitrogen), 2 mg/ml L-glutamine (Invitrogen), 100 unit/ml penicillin (Invitrogen) and 
5 ng/ml bFGF (Peprotech, UK), and cultured at 37oC in a 5% CO2 atmosphere.  
After every 3 days, the current culture medium which contained non-adherent 
cells was replaced with the fresh medium and the cells were maintained until 
reaching 80% confluence. Then, the cells were characterized for MSCs properties 
and passaged for further experimental purposes. The frozen cell stocks were made 
using Cell Banker solution (ZENOAQ, Japan) and kept in -80oC overnight, then 
stored in liquid nitrogen for further experiments. The AT-MSCs used in this study 
were passaged less than 8 total times. 
 
2.2.2. FACS analysis of AT-MSCs 
 To purify AT-MSCs, CD45+ and CD31+ cells were eliminated from adherent cells 
in tissue culture dishes by FACS (MoFlo XDP; Beckman Coulter, State), as 
described previously [41].  
The following antibodies were used for the analysis of AT-MSC markers: 
Fluorescein isothiocyanate (FITC)-labeled anti-HLA-ABC (311404, BioLegend, CA), 
FITC-labeled anti-CD90 (328107, BioLegend), FITC-labeled anti-CD34 (555821, BD 
Biosciences, CA), phycoerythrin (PE)-labeled anti-CD13 (301701, BioLegend), PE-
labeled antti-CD166 (559263, BD Biosciences), PE-labeled anti-CD105 (323206, 
BioLegend), PE-labeled anti-CD73 (550257, BD Biosciences), PE-labeled anti-HLA-
DR (307606, BioLegend), PE-labeled anti-CD31 (303106, BioLegend), PE-labeled 
anti-CD14 (301806, BioLegend), and allophycocyanine (APC)-labeled anti-CD45 
(555485, BD Biosciences). FITC-labeled anti-IgG1 (555748, BD Biosciences), APC-
labeled anti-IgG1 (555751, BD Biosciences), and PE-labeled anti-IgG1 (555749, BD 
Biosciences) were used as the isotype controls. 
 
2.2.3. The differentiation of AT-MSCs 
AT-MSCs are characterized by their adherence, fibroblast-like morphology and 
their capacity to differentiate into specific cell lineages, including adipocytes, 
chondrocytes and osteoblasts [41]. 
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For adipogenic differentiation, cells were cultured in culture medium until 80% 
confluency, then changed into adipogenic differentiation medium containing 
0.1×10−6M dexamethasone (Invitrogen), 0.1mM indomethacin (Invitrogen), and 2 
μg/ml insulin (Invitrogen). After 20 days, adipocytic differentiation was confirmed by 
Oil Red O staining (Wako, Japan).  
For chondrogenic differentiation, the cells were incubated at 5×104 cells/well in 
culture medium for 1 h to achieve micromass formation then changed to the medium 
supplemented with 0.1×10−6M dexamethasone (Invitrogen), 0.25mM ascorbic acid 
(Invitrogen), 40ng/ml proline (Invitrogen), and 10 ng/ml of transforming growth factor 
β3 (TGFβ3, Invitrogen) for 7 days. Chondrogenic differentiation was confirmed by 
hematoxylin and eosin staining (Muto Pure Chemicals, Japan) and Toluidine blue 
staining (Muto Pure Chemicals) and visualized under a microscope (Olympus, 
Japan).  
For osteogenic differentiation, adherent cells were grown in culture medium until 
80% confluency, then changed to osteogenic differentiation medium containing 
0.1×10−6M dexamethasone (Invitrogen), 0.2mM ascorbic acid (Invitrogen), and 
10mM β-glycerophosphate (Invitrogen). After 20 days of culture, calcium deposits 
were detected by Alizarin Red staining (Wako). 
 
2.2.4. The cell proliferation assay 
AT-MSCs were seeded in 35-mm tissue culture dishes (Sumitomo, Japan) at a 
density of 5x104 cells/dish in culture medium and cultured for 10 days. The cell 
culture medium was changed after 3 days. The cells were washed with sterile PBS 
and treated with 0.05% trypsin/EDTA (Invitrogen) at 24-h intervals for 10 days to 
separate single cells. Dead cells were excluded using trypan-blue staining solution 
(Invitrogen) and the numbers of live cells in triplicate dishes were counted using a 
hemocytometer. 
 
2.2.5. Reverse transcription–polymerase chain reaction (RT–PCR) and 
quantitative real-time polymerase chain reaction (qRT-PCR) 
AT-MSCs were maintained under normoxic conditions until reach 80% 
confluency. Then, the cells were put under hypoxic condition with 1% oxygen; cells 
under normoxic condition were used as the control. After 6 hours incubation, cells 
were collected and AT-MSC total RNA was prepared using Sepasol-RNA I Super G 
(Nacalai, Japan) according to the manufacturer's instructions. One microgram of 
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total RNA was reverse transcribed to cDNA using a reverse transcriptase (RT)-
polymerase chain reaction (PCR) kit (Toyobo, Japan).  
The resulting cDNAs were analyzed using a GeneAmp PCR System (Life 
technologies, CA) with 23–35 cycles of denaturation at 95oC for 5 seconds followed 
by anneal and extension at 68oC for 30 seconds then a fluorescence read step. The 
reaction mixtures for the quantitative PCR were prepared using SYBRGreen 
Realtime PCR mastermix (Toyobo) and analyzed using a GeneAmp 7500Fast 
Realtime PCR System (Life Technologies). The sequences of primers used for the 
PCR reactions are listed in Table 1. The experiments were performed in triplicate 
and data were calculated by the double delta cycle number of threshold (Ct) 
method. 
 
2.2.6. Western blotting 
After reaching 80% confluency, AT-MSCs were put under hypoxic condition with 
1% oxygen, or kept under normoxic condition as the control. After 8-hour incubation, 
cells were harvested and nuclear protein was extracted according to the 
manufacturer’s protocol (ThermoFisher Scientific, MA). The extracted protein was 
then mixed with sodium dodecyl sulfate (SDS) loading buffer (Wako) and heated at 
95oC for 3 minutes. Equal amounts of protein were separated through SDS–
polyacrylamide gels and transferred onto PVDF membranes (EMD Millipore, 
Germany) for Western blotting.  
Then, the membranes were immunoblotted with primary antibodies, including 
rabbit anti-Hypoxic-inducible factor-1(HIF-1 (NB100-105, Novus Biologicals, 
CO) and rabbit anti-prolyl-hydroxylase domain-2 (PHD-2) (D31E11, Cell Signaling 
Technology, MA). Goat anti-Lamin B antibody (sc-6217, Santa Cruz Biotechnology, 
CA) was used to monitor protein loading and transfer. Horseradish peroxidase 
(HRP)-conjugated rabbit anti-goat IgG (sc-2768, Santa Cruz Biotechnology), and 
HRP-conjugated goat anti-rabbit IgG (sc2030, Santa Cruz Biotechnology) were 
used as secondary antibodies. The signals were detected by incubating the 
membrane with an enhanced chemiluminescence HRP substrate (EMD Millipore) 
for 1 minute and visualized using an Image Quant LAS 4000 System (GE Healthcare 
Life Sciences, UK).  
 
2.2.7. Measurement of the intracellular ROS level 
 The intracellular ROS level of AT-MSCs was measured by staining the cells with 
ROS indicated reagent, 2',7'-dichlorodihydrofluorescein diacetate (H2-DCFDA, 
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Invitrogen), according to the manufacturer’s instructions. Briefly, after reaching 80% 
confluency, the culture medium was remove and the cells were washed with PBS 
and incubated with PBS containing 10M DCFDA at 37oC for 30 minutes. The 
fluorescence signal was observed under the microscope and the fluorescence 
intensity was analyzed by absorbance at 495 nm and 525 nm wavelengths using a 
photoemission spectrophotometer (Corona Electric, Japan). 
 
2.2.8. The skin flap mouse model 
 Male C57BL/6 mice were purchased from Charles River Japan, Inc. (Japan), 
given food and water ad libitum and maintained in a 12-hour- light/dark cycle in the 
Animal Research Center of the University of Tsukuba. All animal experiments were 
approved by the Animal Care Committee of the University of Tsukuba.  
 The skin flap mouse models were performed as described previously [42]. Male 
10-week-old C57BL/6 mice were anesthetized and the skin on the dorsal surface 
was cut into a peninsular-shaped incision (3cm × 2cm) to creat an ischemic gradient 
by blood flow restriction. The mice were divided into 4 groups: no operation (n=5); 
sham injection with PBS (n=5); nAT-MSCs injection (n=15); and CKD-AT-MSCs 
injection (n=15). On the first day after the surgical process, a total of 5x105 cells were 
intramuscularly injected into four divided sites of the flap skin. Cyclosporin-A (20 
mg/kg body weight; Wako) was intraperitoneally injected into the mice every 2 days 
to induce immunosuppression [38].  
The wound healing of the flap tissues was analyzed at 2 time points (3-day and 
7-day post-transplantation) based on 2 criteria (the inflammatory effect after 3 days 
of transplantation and the necrotic area after 7 days of transplantation.) After 3 days, 
mice were sacrificed, the flap tissues were sectioned and stained with inflammatory 
cell marker, macrophage marker to analyze the inflammatory activity and the 
function to recruit macrophages. After 7 days, images of the ischemic flaps were 
captured and the necrotic areas were analyzed using Image J software (NIH, MD). 
The flap tissues then were sectioned and stained with endothelial markers. 
 
2.2.9. Histological analysis  
 The frozen flap tissue sections were mounted, stained with hematoxylin and 
eosin (Wako) and observed under a microscope (Olympus) for the tissue structure. 
Immunohistochemical staining was used to analyze the function of AT-MSCs in 
recruiting the inflammatory cells and the vessel formation at the wound sites. The 
inflammatory cells recruited in the ischemic area were visualized by staining with 
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PE-labeled anti-CD45 (30F11, BD BioLegend), and PE-labeled anti-Mac1 (561001, 
BD BioLegend). The vessel formation was identified by staining with PE-labeled anti-
31 (557355, BD BioLegend). The numbers of positive cells were counted in ten fields 
and the average was calculated.  
 
2.2.10. Establishment of PHD-2 knoCRFown MSCs  
OmicsLink shRNA Expression Clone targeted to PHD-2 (GeneCopoeia, USA) 
were treansfected into HEK293T cells using the Lenti-Pac HIV Expression 
Packaging Kit (GeneCopoeia) and viral particles were collected then infected to 
target MSCs and selected with puromycin. The PHD-2 expression was confirmed by 
qRT-PCR.  
 
2.2.11. Statistical analysis 
The data were analyzed by ANOVA analysis. SPSS software (IBM Corp., NY) 
was used to perform the statistical analyses. P values of <0.05 were considered 
significant. The data are presented as the mean ± standard deviation (SD). 
 
2.3. Results 
2.3.1. A temporary treatment of uremic toxins causes the ROS accumulation 
and reduced expression of antioxidant-related genes in AT-MSCs  
It is reported that uremic toxins such as p-cresol (an end-product of protein 
metabolism and greatly increased in CRF) increase the expression of intracellular 
ROS in many types of cells [43,44].  
Firstly, to investigate the influence of uremic toxin on the redox state of AT-
MSCs, I treated the AT-MSCs from normal renal function donors (nAT-MSCs) with p-
cresol and evaluated the intracellular ROS level. I observed the change of AT-MSCs 
morphology before and after treatment and found that treatment with p-cresol at low 
concentration (20M) for short periods (24 hours) had no effect on cell viability and 
morphology under normoxic and hypoxic conditions (Fig. 1A).  
To examine the redox state of AT-MSCs under the effect of uremic toxin, the 
intracellular ROS levels were examined by using CM-H2DCFDA, a ROS indicator (Fig. 
1A). I found that the intracellular ROS level was greatly increased in the presence of 
p-cresol under both normoxic and hypoxic conditions (2.3-fold increase under 
normoxic conditions; 3-fold increase under hypoxic conditions, n=3, P<0.05). 
Furthermore, the intracellular ROS accumulation was also observed in nAT-MSCs 
treated with other uremic toxins, hippuric acid (HA) and indoxyl sulfate (IS) (Fig 1B). 
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In order to examine whether the cells were able to reduce ROS levels following 24-
hour period of p-cresol treatment, the nAT-MSCs were continued to culture in the 
absence of p-cresol and passaged for several times. I found that the elevated ROS 
levels were decreased to baseline after 6 passages of cells (Fig. 1C).  
 
Fig 1. A temporary treatment of uremic toxins causes the reduced ROS 
accumulation in AT-MSCs. p-cresol, hippuric acid (HA) and indoxyl sulfate (IS) were used 
as uremic toxins. nAT-MSCs were induced with uremic toxins for 24 hours before analysis. (A) 
Morphology and ROS level in nAT-MSCs and p-cresol- treated nAT-MSCs. (B) Determination 
of the influence of HA and IS on ROS level in  AT-MSCs. (C) Determination of the reduction 
of ROS level in nAT-MSCs following p-cresol treatment. The p-cresol-treated nAT-MSCs were 
continued to culture in the absence of p-cresol and passaged for several times then measured 
the fluorescence signal of ROS. nAT-MSCs without p-cresol treatment was used as the 
control. The data represent the mean ± SD. n=3, *P<0.05, ns: no significance. The experiments 
were performed in triplicate. White bar represents the normoxic condition; black bar represents 
the hypoxic condition. 
 
MSCs are known to constitutively express high levels of antioxidant enzymes, 
which can regulate the balance of intracellular ROS [46]. Next, I checked the 
expression of antioxidant enzymes in MSCs under the presence of uremic toxins. As 
expected, I found that the treatment with p-cresol resulted in a significant reduction of 
the mRNA expression levels of antioxidant enzyme genes such as SOD1, GPX1 and 
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catalase in nAT-MSCs under both normoxic and hypoxic conditions (SOD1 
expression: 3.4-fold decrease, GPX1: 5.6-fold decrease, catalase: 3.1-fold decrease 
in the presence of p-cresol under normoxic conditions, n=3, P<0.05) (Fig 2A). 
Consistent with the decrease of the elevated ROS levels, after nAT-MSCs were 
continued to culture in the absence of p-cresol and passaged for several times, mRNA 
levels of antioxidant enzyme genes were restored after 6 passages of cells (Fig 2B).  
 
 
Fig 2. A temporary treatment of uremic toxins causes the expression of antioxidant-
related genes. (A) The mRNA expression of antioxidant genes in nAT-MSCs and p-cresol-
treated nAT-MSCs. (B) Determination of the recovery of antioxidant enzyme genes expression 
in nAT-MSCs following p-cresol treatment under normoxic and hypoxic conditions. The p-
cresol-treated nAT-MSCs were continued to culture in the absence of p-cresol and passaged 
for several times then analysed the expression of antioxidant genes. nAT-MSCs without p-
cresol treatment was used as the control. The data represent the mean ± SD. n=3, *P<0.05, 
ns: no significance. The experiments were performed in triplicate. White bar represents the 
normoxic condition; black bar represents the hypoxic condition. 
 
Collectively, these results indicate that uremic toxins causes the ROS accumulation 
in nAT-MSCs. The attenuated expression of antioxidant enzyme genes by uremic 
toxins is the cause of the elevation of ROS in the cells. 
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2.3.2. A temporary treatment of uremic toxins causes the impaired hypoxic 
response and loses wound healing activity in AT-MSCs 
Hypoxia inducible factor-1 (HIF-1) is a key transcriptional factor in the 
response to hypoxic stimuli and regulates the expression of many target genes 
which play essential roles in the function of MSCs. ROS is known to be involved in 
the regulation of HIF-1 but the role of ROS in the stability of HIF-1 remains 
controversial. To investigate whether the induction of intracellular ROS by uremic 
toxin affects the stability of HIF-1, I evaluated the mRNA and protein levels of HIF-
1 in the uremic toxin-treated nAT-MSCs.  
The HIF-1 protein was almost undetectable under normoxic conditions and 
clearly detected under hypoxic conditions in the untreated nAT-MSCs (Fig. 3A). 
Remarkably, the HIF-1 protein level was significantly reduced under hypoxic 
conditions in the uremic toxin-treated cells (Fig. 3A). The HIF-1 mRNA levels were 
largely unaffected by the p-cresol treatment (Fig. 3A). Consistent with these 
observations, the mRNA levels of HIF-1target genes VEGF and SDF-1 were 
significantly reduced by the p-cresol treatment under hypoxic conditions (VEGF: 3.7-
fold decreased expression; SDF-1: 2.3-fold decreased expression, n=3, P<0.05, Fig. 
3B).  
My laboratory previously showed that an injection of nAT-MSCs into the injured 
area facilitates healing process in a mouse skin flap wound model and HIF factors 
play key roles for the wound healing capability [47,48]. Because both VEGF (which 
is involved in angiogenesis) and SDF-1 (which is involved in migration) are major 
factors to promote the wound healing activity, I surmised that the uremic toxin-
treated nAT-MSCs may have defective wound healing capability in this model. As 
expected, the p-cresol treatment almost completely lost the wound-healing effect of 
nAT-MSCs as revealed by the size of necrotic area on post-transplantation day 7 
(uremic toxin-treated nAT-MSCs: 55.08±7.21% vs nAT-MSCs: 28.23±8.05%, n=3, 
P<0.05, Fig. 3C). These data indicate that uremic toxins causes the impaired 
hypoxic response and loses the wound healing activity of nAT-MSCs. 
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Fig 3. A temporary treatment of uremic toxins causes the impaired hypoxic response 
and loses wound healing activity in AT-MSCs. (A) The mRNA expression of  HIF-1 and 
HIF-1 protein expression in untreated nAT-MSCs and p-cresol-treated nAT-MSCs. (B) The 
mRNA expression of VEGF and SDF-1 was determined in  untreated nAT-MSCs and p-cresol-
treated nAT-MSCs. (C) Necrotic areas of the skin flaps of mice injected with PBS, nAT-MSCs 
and p-cresol-treated nAT-MSCs on post-transplantation day 7. The data represent the mean 
± SD. n=3, *P<0.05, ns: no significance. The experiments were performed in triplicate. White 
bar represents the normoxic condition; black bar represents the hypoxic condition. 
 
2.3.3. AT-MSCs isolated from the stages 3-4 of CKD patients showed the 
typical characteristics of mesenchymal stem cells  
I next examined AT-MSCs derived from CKD stage 3-4 patients, which supposed 
to be continuously exposed to uremic toxins in the patient body. Prolonged exposure 
of uremic toxins often results in the damage of multiple tissues and cell types resulting 
in secondary organ failure at the terminal stage of CRF. Therefore, to investigate 
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direct effects of uremic toxins, I have chosen the stage 3-4 of CKD patients as donors 
of AT-MSCs. 
Firstly, I characterized the morphology, proliferation /differentiation abilities, and 
the expression of MSC cell surface markers of CKD-derived MSCs (CKD-AT-MSCs), 
comparing with those from non-CKD donors. Both nAT-MSCs and CKD-AT-MSCs 
had a fibroblast-like morphology, were spindle-shaped, and showed no significant 
difference in the proliferative ability (Fig. 4A-B). Similar to nAT-MSCs, CKD-ATMSCs 
expressed the typical markers of MSCs, such as CD13, CD90, CD73, and CD105, 
and negative with CD31, CD45 markers (Fig. 4C). In addition, CKD-AT-MSCs showed 
a similar ability to nAT-MSCs to differentiate into osteoblasts, adipocytes and 
chondrocytes (n=5 in each, P<0.05, Fig. 4D).  
 
Fig 4. AT-MSCs isolated from CKD patients show the typical characteristics of MSCs. 
(A) Morphology of AT-MSCs. (B) Growth curve of AT-MSCs. (C) Marker profile of AT-MSCs. 
(D) Differentiation ability to osteocytes, adipocytes, and chondrocytes of AT-MSCs after 20 
days. nAT-MSCs. n=5. The scale bar indicates 100 m. The experiments were performed in 
triplicate. Open square represents the nAT-MSCs; open circle represents the CKD-AT-MSCs. 
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Therefore, I concluded that the AT-MSCs isolated from the CKD patients show 
the typical MSCs characteristics which have fibroblast-like morphology, expressed 
typical markers of MSCs, have the ability to proliferate and differentiate to the 
mesoderm cell lineages, include osteoblasts, adipocytes and chondrocytes. 
 
2.3.4. AT-MSCs isolated from the CKD patients exhibits high levels of 
intracellular ROS and impaired hypoxic response  
To examine that not only treatment under in vitro culture, in vivo conditions of 
uremic toxins have the similar influence on AT-MSCs, I then examined whether the 
intracellular ROS levels were increased in the CKD-derived MSCs as the results I 
observed in the p-cresol-treated nAT-MSCs.  
 
Fig 5. AT-MSCs isolated from CKD patients exhibit high levels of intracellular ROS and 
impaired antioxidant genes. (A) Determination of intracellular ROS level in AT-MSCs by 
staining with H2-DCFDA. (B) The mRNA expression of antioxidant genes in AT-MSCs. The 
data represent the mean ± SD. n=5, *P<0.05, ns: no significance. The scale bar indicates 100 
m. The experiments were performed in triplicate. White bar represents the normoxic 
condition; black bar represents the hypoxic condition. 
 
I found that even in the absence of the exogenous administration of uremic 
toxins, the ROS generation in CKD-AT-MSCs was higher than that in nAT-MSCs 
under both normoxic and hypoxic conditions (2.3-fold higher in normoxic condition 
and 2.7-fold higher in hypoxic condition, n=4, P<0.05) (Fig. 5A). Moreover, consistent 
with the case of the p-cresol-treated nAT-MSCs, the mRNA expression levels of 
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antioxidant enzyme genes (SOD1, GPX1, and catalase) were significantly lower in 
CKD-AT-MSCs than those in nAT-MSCs (SOD1: 9.72-fold lower; GPX1: 9.23-fold 
lower; Catalase: 19-fold lower, respectively in AT-MSCs, n=4, P<0.05) (Fig. 5B).  
Collectively, these data indicate that the antioxidant ability was severely 
impaired in CKD-AT-MSCs. 
I next examined whether the hypoxic response of HIF-1 protein is altered in 
the CKD-derived MSCs.  
 
 
Fig 6. AT-MSCs isolated from the CKD patients have the impaired hypoxic response. 
(A) The mRNA and protein expression of HIF-1 in AT-MSCs was examined by qRT-PCR and 
Western blotting, respectively. (B) The mRNA expression of HIF-1 target genes in AT-MSCs. 
The data represent the mean ± SD. n=5, *P<0.05, ns: no significance. The scale bar indicates 
100 m. The experiments were performed in triplicate. White bar represents the normoxic 
condition; black bar represents the hypoxic condition. 
Similar to the case of the p-cresol-treated nAT-MSCs, the HIF-1 protein level 
was significantly lower in CKD-AT-MSCs compared to nAT-MSCs under hypoxic 
conditions, whereas the mRNA expression level was comparable in these cells (Fig. 
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6A). In association with the reduction of HIF-1 protein, the mRNA levels of VEGF, 
SDF-1 and TGF-were significantly reduced under hypoxic conditions (Fig. 6B). By 
contrast, the moderate increase of bFGF mRNA expression was retained in CKD-AT-
MSCs under hypoxic conditions. In addition, the expression of a CXC chemokine 
receptor CXCR4, another HIF-1target gene in macrophages, endothelial cells and 
cancer cells [48], was not increased in nAT-MSCs and CKD-AT-MSCs under hypoxic 
conditions (Fig. 6B). 
 
2.3.5. CKD-AT-MSCs exhibit impaired wound healing ability 
I thought that the reduced expression of HIF-1 target genes might affect the 
wound healing capacity of CKD-AT-MSCs in vivo. To test this possibility, I examined 
whether an injection of CKD-MSCs into the injured area facilitates healing process as 
nAT-MSCs did in a mouse skin flap wound model.  
Compared to the mice injected with nAT-MSCs, those with CKD-AT-MSCs 
revealed larger unhealed wound area on post-transplantation day 7 (Fig. 7A). The 
area of wound site was comparable to the control mice, indicating that CKD-AT-MSCs 
are incapable of facilitating physiological healing process (the necrotic area: sham 
control (PBS): 60.02±9.33%, CKD-AT-MSCs: 73.34±7.02% vs nAT-MSCs: 
37.52±8.13%, n=3, P<0.05).  
 The histological analysis of wound healing process showed that the numbers of 
CD45-positive cells and Mac1-positive monocytes/macrophages were significantly 
increased in the ischemic area of nAT-MSC injected mice on post-transplantation day 
3, which indicated that nAT-MSCs possessed a chemoattractive activity that recruited 
inflammatory cells to the site of tissue damage. In contrast to these observations, 
lesser numbers of migrated inflammatory cells were observed in CKD-AT-MSC 
injected mice (CD45-positive cells, CKD-AT-MSCs: 70±14 / field vs nAT-MSCs: 
173±19, n=3, P<0.05; Mac-1-possitive cells, CKD-AT-MSCs: 66±9 / field vs nAT-
MSCs: 158±14, n=3, P<0.05, Fig. 7B-C).  
On the seventh day of transplantation, the greater number of CD31-positive 
endothelial cells was appeared in the subcutaneous region of nAT-MSC injected flap 
compared with that of PBS injected controls. In contrast, when CKD-AT-MSCs were 
transplanted at the flap site, the number of CD31-positive cells was comparable to the 
controls (CD31-posstive cells, CKD-AT-MSCs: 438±105 / field vs nAT-MSCs: 
1292±291, n=3, P<0.05) (Fig. 7C).  
Taken together, unlike nAT-MSCs, CKD-AT-MSCs failed to promote the wound 
healing process throughout the stage in the mouse skin flap wound model.  
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Fig 7. CKD-AT-MSCs exhibit impaired wound healing ability. (A) Necrotic areas of skin 
flaps on post-transplantation day 7. (B) The HE staining, PE-labeled anti-CD45, PE-labeled 
anti-Mac1 on the third day of transplantation and PE-labeled anti-CD31 on the seventh day of 
transplantation. The data represent the mean ± SD. n=3, *P<0.05, ns: no significance. The 
experiments were performed in triplicate. The brown dots indicate positive cells. 
2.3.6. Treatment of CKD-AT-MSCs with an ROS inhibitor restores the impaired 
HIF-1 expression under hypoxic conditions 
To explore a direct link between the ROS accumulation and the impaired 
hypoxic response in CKD-AT-MSCs, I next examined whether treatment with an ROS 
inhibitor (N-acetyl-L-cysteine, NAC) can restore the reduced HIF-1 expression in 
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CKD-AT-MSCs under hypoxic conditions. CKD-AT-MSCs treated with NAC showed 
a decrease of intracellular ROS and upregulation of mRNA levels of antioxidant 
enzymes SOD1, GPX1, and catalase, indicating that the reduced expression of these 
genes was wholly dependent on ROS (Fig. 8A).  
 
Fig 8. Treatment of CKD-AT-MSCs with an ROS inhibitor restore the oxidative balance. 
1M N-acetyl-L-cysteine (NAC) was used as ROS inhibitor. (A) The intracellular ROS level in 
CKD-AT-MSCs was determined in the absence or presence of a ROS inhibitor under normoxic  
or hypoxic conditions and compared to nAT-MSCs. (B) The mRNA expression of antioxidant 
genes in CKD-AT-MSCs was determined in the absence or presence of a ROS inhibitor under 
normoxic or hypoxic conditions. White bar represents the normoxic condition; black bar 
represents the hypoxic condition. 
Of note, the NAC treatment also restored the hypoxic induction of HIF-
1protein in CKD-AT-MSCs, which was 5.7-fold higher level than that observed in 
the control cells (n=4, P<0.05) (Fig. 9A). Accordingly, the expression of VEGF and 
SDF-1 was increased in the NAC-treated CKD-AT-MSCs compared to that in the 
untreated cells under hypoxic conditions (3-fold and 2.5-fold higher, respectively, n=4, 
P<0.05, Fig. 9B). These results strongly indicate that the high level of ROS in CKD-
AT-MSCs impairs their wound healing activity by attenuating the hypoxic induction of 
HIF-1protein and the expression of hypoxia-inducible genes.  
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Fig 9. Treatment of CKD-AT-MSCs with an ROS inhibitor restores the hypoxic induction. 
1M N-acetyl-L-cysteine (NAC) was used as ROS inhibitor. (A) Western blotting analysis of  
HIF-1 protein expression in CKD-AT-MSCs. (B) The mRNA expression of VEGF and SDF-1 
were determined in CKD-AT-MSCs in the absence or presence of a ROS inhibitor. The data 
represent the mean ± SD. n=5, *P<0.05. The experiments were performed in triplicate. White 
bar represents the normoxic condition; black bar represents the hypoxic condition. 
2.3.7. Increased expression of prolyl hydrolase domain 2 (PHD-2) is 
responsible for HIF-1 dysregulation in CKD-AT-MSCs 
As shown above, the expression of HIF-1protein, but not transcript, was 
decreased both in the p-cresol-treated nAT-MSCs (Fig. 3A) and in CKD-AT-MSCs 
(Fig. 6A) under hypoxic conditions. To define the molecular basis of these findings, I 
examined the contribution of the oxygen-responsive prolyl hydroxylases (PHDs) that 
are known to play key roles in the regulation of HIF-1protein [50]. PHDs hydroxylate 
specific proline residues of HIF-1in the oxygen-dependent degradation (ODD) 
domain of this protein [50]. This domain is recognized by the von Hippel-Lindau tumor-
suppressor protein (VHL), a component of an E3 ubiquitin ligase complex that results 
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in the rapid proteasomal degradation of HIF-1 [50]. Hypoxia reduces the activity of 
PHDs, thereby stabilizing HIF-1 protein.  
On the basis of these previous findings, I hypothesized that the intracellular 
accumulation of ROS might keep PHDs in active state, leading to continuous 
degradation of HIF-1protein even under hypoxic conditions. To test this possibility, 
I firstly examined the mRNA levels of PHD genes (PHD1, PHD2 and PHD3) by 
quantitative RT-PCR. As previously reported [51], the expression of all PHD genes is 
induced by hypoxia (Fig. 10A). Interestingly, the expression level of PHD-2 was more 
than doubled in CKD-AT-MSCs compared to that in nAT-MSCs under hypoxic 
conditions (2.4-fold higher than nAT-MSCs, n=4, P<0.05). On the other hand, those 
of PHD-1 and PHD-3 were comparable between CKD-AT-MSCs and nAT-MSCs (Fig. 
10A). Consistent with the increased mRNA expression, the PHD-2 protein level was 
increased in CKD-AT-MSCs compared to that in nAT-MSCs under hypoxic conditions 
(Fig. 10A-B).  
 
Fig 10. Increased expression of prolyl hydrolase domain 2 (PHD-2) in CKD-AT-MSCs. 
(A) mRNA expression of PHDs in AT-MSCs. (B) Western blotting of PHD-2 protein expression 
in AT-MSCs. The data represent the mean ± SD. n=3, *P<0.05, ns: no significance. The 
experiments were performed in triplicate. White bar represents the normoxic condition; black 
bar represents the hypoxic condition. 
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To examine whether the inhibition of PHD-2 is capable of restoring the hypoxia-
induced stabilization of HIF-1 protein, CKD-AT-MSCs were pretreated with a PHD-
2inhibitor (N-[[1,2-dihydro-4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl] carbonyl]-
glycine, IOX2) and were cultured under hypoxic conditions. As expected, the HIF-1 
protein level was higher in the IOX2 treated CKD-AT-MSCs (Fig. 11A). Accordingly, 
the mRNA levels of VEGF and SDF-1 in CKD-AT-MSCs were significantly higher in 
these cells (3-fold increase in IOX2-treated CKD-AT-MSCs, n=4, P<0.05, Fig. 11B).  
 
Fig 11. Inhibition of prolyl hydrolase domain 2 (PHD-2) expression restores hypoxic 
induction in CKD-AT-MSCs. 50 M IOX2 was used as PHD2 inhibitor. (A) HIF-1 protein 
expression in CKD-AT-MSCs. (B) The mRNA expression of VEGF and SDF-1 in CKD-AT-
MSCs in the absence or presence of PHD-2 inhibitor. The data represent the mean ± SD. n=3, 
*P<0.05, ns: no significance. The experiments were performed in triplicate. White bar 
represents the normoxic condition; black bar represents the hypoxic condition. 
I further examined whether similar results were observed in CKD-AT-MSCs 
transduced with small hairprin RNA (shRNA) against PHD-2 gene (KD-PHD-2-CKD-
AT-MSCs). The mRNA level of PHD-2 in these cells was reduced to a similar level of 
that in nAT-MSCs (3.39-fold decrease under normoxic conditions; 2.3-fold decrease 
under hypoxic conditions, n=3, P<0.05, Fig. 12A). Consistent with the results from 
IOX2 treated CKD-AT-MSCs, HIF-1 protein was clearly detectable in KD-PHD-2, 
but not control siRNA transduced CKD-AT-MSCs (Fig. 12B). The mRNA levels of 
VEGF and SDF-1 in KD-PHD-2-ATMSCs were comparable to those in nAT-MSCs 
under hypoxic conditions (Fig. 12C). Lastly, I examined whether KD-PHD-2-CKD-AT-
MSCs can facilitate wound healing process as nAT-MSCs do in a mouse skin flap 
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wound model. Indeed, KD-PHD-2-CKD-AT-MSCs showed the recovery of wound 
healing similar to the control nAT-MSCs (Fig. 12D).  
 
 
Fig 12. Knockdown of prolyl hydrolase domain 2 (PHD-2) expression restores hypoxic 
induction and wound healing function of CKD-AT-MSCs. (A) The mRNA expression of 
PHD-2 in nAT-MSCs, CKD-AT-MSCs (Control) and CKD-AT-MSCs knockdown PHD-2 (KD-
PHD-2). (B) HIF-1 protein expression in AT-MSCs. (C) The mRNA expression of VEGF and 
SDF-1 in AT-MSCs. (D) Necrotic areas of the skin flaps of mice injected with PBS, nAT-MSCs, 
CKD-AT-MSCs Control and CKD-AT-MSCs KD-PHD-2 on post-transplantation day 7. The 
data represent the mean ± SD. n=3, *P<0.05, ns: no significance. The experiments were 
performed in triplicate. White bar represents the normoxic condition; black bar represents the 
hypoxic condition. 
Taken altogether, these data indicate that hypoxic stabilization of HIF-1 protein is 
impaired in CKD-AT-MSCs accumulating high level of ROS derived from uremic toxins. 
My data suggest that the impaired hypoxic induction of HIF-1 and functional failure in 
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wound healing in CKD-AT-MSCs can be restored by inhibition of PHD-2, which is 
selectively upregulated in these cells. 
 
2.4. Discussion 
The present study demonstrated that AT-MSCs isolated from stage 3 and 4 of CKD 
patients (CKD-AT-MSCs) had an impaired wound healing capacity due to the impaired 
of antioxidant enzymes and elevated ROS which are involved in the absence of hypoxic 
induction of HIF-1 protein. The hypoxia responsible genes related to angiogenesis and 
recruitment of inflammatory cells, such as VEGF and SDF, were downregulated in these 
cells. Importantly, my data showed that the inability of HIF-1 activation is largely 
attributed to the increased PHD2 expression in CKD-AT-MSCs under hypoxic conditions. 
Moreover, correcting the intracellular ROS level restores the hypoxic induction of HIF-1 
in these cells, resulting in the recovery of wound healing activity. 
 
2.4.1. Uremic toxins, which accumulated in CRF progression, caused the 
reversible imbalance of oxidative balance and defective functions of AT-MSCs 
in wound healing 
In CKD patients with progressive impairment of kidney function have the 
accumulation of uremic toxins [5]. When the uremic toxins amount exceeds in the 
body, it causes negative impact to organs, tissues, and cells including stem cells. 
Previous report showed that uremic toxins at high concentration causes the altered 
paracrine activity of MSCs in vitro, decrease VEGF and TGF-1 expression which 
implied the altered function of MSCs [35]. However, the influence of uremic toxins at 
low concentration on AT-MSCs is not yet identified. In the present study, I clarified 
whether uremic toxins at low concentration cause any impaired function of AT-MSCs. 
I focused on the oxidative balance and wound healing functions of AT-MSCs, which 
are associated with the retention of uremic toxins in CRF. Interestingly, I found that 
treatment with uremic toxin at low concentration definitely caused the elevated ROS, 
impaired the hypoxic induction of AT-MSCs and led to the dysfunction of AT-MSCs in 
wound healing.  
To address the underlying mechanism involved in the increased ROS 
accumulation, I analyzed the antioxidant-related enzymes which maintain the balance 
of the redox state in the body [52]. Among the antioxidant enzymes controlling the 
balance of redox state in the cell, superoxide dismutase oxidases (SODs), which 
catalyze the dismutation of superoxide radicals into either oxygen (O2) or hydrogen 
peroxide (H2O2), are considered to be one of the most important antioxidant enzymes 
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[53]. The H2O2 is  then degraded by other enzymes, such as glutathione peroxidase 
and catalase [54]. Indeed, I found that uremic toxins impaired the expression of some 
antioxidant enzymes, including SOD1, GPX1 and catalase, which can explain why 
the high level of ROS induced the defective wound healing in the AT-MSCs (Fig 1). 
Importantly, this effect was remained for a short period of time in culture, and was 
cancelled after prolonged culture. 
 
2.4.2. AT-MSCs derived from stage 3-4 of CKD patients showed the typical 
characteristics of AT-MSCs, but abnormal ROS expression 
Studying the characteristics and functions of AT-MSCs isolated from CRF 
patients who have the retention of uremic toxins are necessary to apply for clinical 
therapy, especially auto-transplantation. Up to now, regarding to CRF and MSCs, 
most of the previous studies used the MSCs isolated from bone marrow or umbilical 
cord blood which derived from ESKD patients [31, 55]. The accumulation of uremic 
toxins is a gradual process which begins from the beginning of pathogenesis [5]. 
Therefore, exacerbations of renal function are associated with the uremic toxins 
accumulation, with low levels of toxic load and high levels in the end stage [5]. Since 
I found that even at low concentration uremic toxins caused the defective functions of 
AT-MSCs, there is a possibility that AT-MSCs derived from the CKD, when the 
accumulation of uremic toxins is mild and moderate in vivo, also have the similar 
defect. Therefore, studying the effect of CRF progression on MSCs is required and 
the data is important for the clinical purpose to apply stem cell therapy to failure 
progress.  
In the present study, I focused on the AT-MSCs isolated from the patients with 
impaired kidney who are at risk to end stage kidney disease (ESKD). I found that AT-
MSCs isolated from CKD patients before ESKD have the typical characteristics of AT-
MSCs. Compared to AT-MSCs derived from non-CRF donors, they have the same 
characteristics in morphology, growth ability, surface marker expression, and 
differentiation abilities to adipocytes, osteoblasts, and chondrocytes. Interestingly, 
while cell proliferation, survival and the ability of differentiation were largely unaffected, 
my data showed that similar to the results of treatment AT-MSCs with uremic toxins 
in vitro, a significant, but reversible, imbalance of ROS and antioxidant enzymes, 
including SOD1, GPX1 and catalase, which caused the defective function in wound 
healing of CRF-AT-MSCs was observed. Although all the samples were derived from 
cardiovascular disease (CVD) patients who are known to have high level of ROS [56], 
with the same background of CVD, AT-MSCs from patients with CRF showed 
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significantly increased expression of ROS compared to non-renal failure cells. This 
suggested that uremic toxins, a consequent from progressed renal failure, might 
cause the increase of ROS production in the cells. However, up to now, how uremic 
toxins regulate the expression of these antioxidant is still unclear. Previously, Bolati 
et al. showed that indoxyl sulfate, a uremic toxin, downregulates the renal expression 
of Nrf2 through the activation of NF-κB in the proximal tubular cells and the kidney of 
a rat model of CRF [58]. NRF-2 is known as a regulator of the expression of direct 
ROS scavenging enzymes, including SOD1, GPX1 and catalase [59]. Therefore, I 
hypothesized that Nrf2 might be involved in this pathway; uremic toxins might 
downregulate the expression of Nrf2, resulting in impaired antioxidant gene 
expression in CRF-AT-MSCs. Further studies are needed to clarify how uremic toxins 
effect on the upstream regulators of antioxidant enzymes that lead to the imbalance 
of redox state in AT-MSCs. 
 
2.4.3. CRF caused the impairment of AT-MSCs function in wound healing from 
the pre-ESKD by the PHD2/ROS pathway   
Recently, Yamanaka et al. reported that AT-MSCs from end-stage kidney 
disease (ESKD) patients who receive long-term dialysis show poor angiogenesis 
activation [31]. In my study, I found that not only ESKD, which is equivalent with stage 
5 of CKD, causes the poor function of AT-MSCs, AT-MSCs isolated from stage 3-4 of 
CKD showed an impaired wound healing capacity. Consistent with previous report 
observations in ESKD, I found that HIF-1 and VEGF expression were not 
upregulated under hypoxic conditions in AT-MSC from CRF. In the case of ESKD 
patients, the expression of PCAF, a histone acetyltransferase, was significantly 
downregulated in AT-MSCs [31]. The expression of PCAF is induced by hypoxia in 
AT-MSCs from healthy controls, but not ESKD patients. Interestingly, I could not find 
any difference in the expression of PCAF between the CRF-AT-MSCs and nAT-MSCs 
while both studies showed an impairment of promoting in vivo angiogenesis in CRF-
AT-MSCs. Furthermore, HIF-1 mRNA levels were comparable between these cells 
under both normoxic and hypoxic conditions. In addition, inhibition of intracellular 
ROS level restores the hypoxic induction of HIF-1 and recovered the cells function. 
Therefore, it is suggested that there is another pathway, related to ROS, which is 
involved in the impaired function of AT-MSCs from CRF without dialysis. 
PHDs are known to act as oxygen sensors whose catalytic activity is oxygen-
dependent [59]. My data demonstrated that HIF-1 protein failed to be stabilized even 
under hypoxic conditions, suggesting that the enzymatic activity of PHDs is persisted, 
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at least in part, under hypoxic conditions in CRF-AT-MSCs. Therefore, I analyzed the 
expression of PHDs in CRF-AT-MSCs under hypoxic conditions. Interestingly, I found 
that only PHD2 expression is specifically increased in CRF-AT-MSCs. Moreover, 
functional failure of AT-MSCs in wound healing activity was fully restored by inhibiting 
PHD2 in CRF. Since the impaired activation of HIF-1 is closely associated with an 
accumulation of intracellular ROS, it is conceivable that ROS is a positive regulator of 
PHD2. In support of this notion, Hellfritsch et al. reported that deletion of mitochondrial 
thioredoxin reductase (Txnrd2) in mouse embryonic fibroblasts and in tumor cells led 
to the increased PHD2 protein expression and the absence of hypoxic induction of 
HIF-1 [60]. In Txnrd2-deficient cells, ROS levels were elevated and PHD2 protein is 
stabilized via c-Jun NH2-terminal kinase (JNK)-dependent mechanism [60].  
Recent studies revealed that the catalytic activity of PHD2 is regulated by a 
complex mechanism involving redox reductions and energy metabolism [61]. Since 
intracellular ROS is known to oxidize ferrous iron, which is an essential cofactor for 
PHD-2 [62], the PHD2 activity of might be persisted with ROS accumulation in cells. 
Taking in other point of view, the enzyme activity of PHD2 is also known to be 
dependent on 2-oxoglutarate (2-OG), an intermediate of tricarboxylic acid cycle [62]. 
Recently, two mitochondrial genes, oxoglutarate dehydrogenase and lipoic acid 
synthase, were identified as novel HIF-1 regulators [62]. Mutation of these genes 
results in 2-OG accumulation and L-2-hydroxyglutarate formation, which inhibits the 
PHD2 activity. The evaluation of oxygen metabolism in the cells with high 
interacellular ROS level might provide helpful information for understanding the 
regulation of PHD2 activity. 
Another pathway that is considered to regulate PHD-2 expression is the TGF1-
Smad pathway [63]. TGF1 has been shown to induce HIF-1 stabilization through 
the selective inhibition of PHD-2 expression [63,64]. As shown in Figure 6B, the 
expression of TGF1 was significantly repressed in CRF-AT-MSCs, although the 
effects of TGF1 reduction have not been examined. Although these pathways might 
explain the increased PHD2 protein level in CRF-AT-MSCs, it remained unsolved that 
PHD2 mRNA level is also upregulated in CRF-AT-MSCs under hypoxic conditions. 
Compared to the posttranscriptional regulation, much less is known about the 
regulation of PHD2 gene transcription. It will be important to address this issue in 
further studies. 
Collectively, these data suggest that mechanisms underlying the impaired 
hypoxic response in CRF-AT-MSCs might change depending on the pathological 
stages of CRF. 
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Chapter III. Conclusion and perspectives 
 
3.1. Conclusions 
In the present study, I demonstrated that there is the relation between uremic toxins 
and oxidative stress in AT-MSCs. Uremic toxins cause the imbalance of intracellular 
ROS by the declined expression of antioxidant enzymes such as SOD1, GPX1, and 
catalase. Importantly, the imbalance of ROS induced by uremic toxin causes the 
impairment of hypoxic induction which causes the lost function of AT-MSCs in wound 
healing. Graduated accumulation of uremic toxins is a common complication happening 
preferred of CRF, suggesting that AT-MSCs isolated from CRF patients who have the 
uremic toxins retention might possess the different characteristics and wound healing 
functions compared to the normal AT-MSCs. 
In addition, I isolated MSCs from CKD patients before dialysis treatment (stage 3-4, 
CKD-AT-MSCs) to clarify whether under a mild accumulated uremic toxins condition, AT-
MSCs were still dramatically impacted. I found that CKD-AT-MSCs show the typical 
characteristics of mesenchymal stem cells, include morphology, MSCs markers, 
proliferation and differentiation abilities. Consistent with the results from normal AT-
MSCs after treating with uremic toxins, CKD-AT-MSCs showed the imbalance of 
antioxidant system and high ROS level. Importantly, I found that there is the high 
expression of PHD2 in CKD-AT-MSCs under hypoxic conditions which cause the lack of 
HIF-1 protein expression and reduced the expression of HIF-1 target genes related to 
the angiogenesis and recruitment of inflammatory cells during the wound healing process. 
The data suggest the negative effect of uremic toxins to the ROS-PHD-2 pathway which 
related to hypoxic induction and wound healing function in AT-MSCs (Fig. 13). 
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Fig 13. The mechanism underlying the defective function in wound healing of AT-MSCs in 
CKD patients. In AT-MSCs, there is a balance of the expression of antioxidant enzymes and 
ROS. Under hypoxic conditions, HIF-1 is stable and induces the expression of target genes 
involved in wound healing. In contrast, in CKD-AT-MSCs, uremic toxins induced the impairment 
of antioxidant enzymes, including SOD1, catalase, and GPX1, resulting in a high level of 
intracellular ROS. ROS can enhance the activity of PHD-2 to hydroxylate HIF-1and the 
degradation of HIF-1occurs even under hypoxic conditions. Consequently, the expression of 
the target genes involved in wound healing are impaired which results in a loss of wound healing 
function in CKD-AT-MSCs. HRE: hypoxic response element 
 
3.2. Perspectives 
In perspective, my study shows that ROS-PHD-2 pathway may be considered 
as a therapeutic candidate to modify the function of CKD-AT-MSCs before using in 
clinical treatment for wound healing delay complication. AT-MSCs isolated from CKD 
patients had an imbalanced redox state and elevated of PHD-2, and showed the 
impairment to repair wounds. Pretreatment of CKD-AT-MSCs with IOX2 alone, or in 
combination with NAC, could be effective to improve their wound healing activity. In 
addition, my data provide critical information for developing a therapeutic strategy in AT-
MSCs-based cell therapy in CKD patients. Special attention should be paid to the 
pathological stage of CRF, since the wound healing activity of AT-MSCs might be 
progressively and irreversibly lost at the end stage of CRF.  
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Tables 
Table 1. The background information of patients from whom adipose tissue derived 
mesenchymal stem cells were isolated 
Donner # Age Sex HbA1c Creatinine (mg/dl) Stage of CRF 
CKD-AT#1 81 M 4.7 1.41 2 
CKD-AT#2 77 M 5.5 1.51 2 
CKD-AT#3 74 M 5.3 1.64 2 
CKD-AT#4 79 M 5.4 2.01 3 
CKD-AT#5 66 M 5.7 1.95 3 
n-AT#1 68 M 5.8 <1 none 
n-AT#2 67 M 4.9 <1 none 
n-AT#3 71 M 4.5 <1 none 
n-AT#4 82 M 4.6 <1 none 
n-AT#5 80 M 5.4 <1 none 
 
Table 2 The primer sets for the quantitative polymerase chain reactions 
Function Gene Primer Sequence 
Internal 
control 
-actin 5’-primer 
3’-primer 
GTGCGTGACATTAAGGAGAAGCTGTGC 
GTACTTGCGCTCAGGAGGAGCAATGAT 
Transcription 
factor 
HIF-1 5’-primer 
3’-primer 
GTTTACTAAAGGACAAGTCACC 
TTCTGTTTGTTGAAGGGAG 
HIF-2 5’-primer 
3’-primer 
TGACAGCTGACAAGGAGAAGAA 
CAGCTCCTCAGGGTGGTAAC 
Angiogenic 
factors, 
cytokines 
and 
chemokines 
VEGF 5’-primer 
3’-primer 
CTACCTCCACCATGCCAAGT 
GCAGTAGCTGCGCTGATAGA 
SDF-1 5’-primer 
3’-primer 
TCTGAGAGCTCGCTTGAGTG 
GTGGATCGCATCTATGCATG 
TGF- 5’-primer 
3’-primer 
AGAGCTCCGAGAAGCGGTACCTGAACCC 
GTTGATGTCCACTTGCAGTGTGTTATCC 
bFGF 5’-primer 
3’-primer 
AGAGCGACCCTCACATCAAGCTACAAC 
ATAGCTTTCTGCCCAGGTCCTGTTTTG 
CXCR4 5’-primer 
3’-primer 
CACTTCAGATAACTACACCG 
ATCCAGACGCCAACATAGAC 
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 CXCR7 5’-primer 
3’-primer 
AAGAAGATGGTACGCCGTGTCGTCTG 
CTGCTGTGCTTCTCCTGGTCACTGGAC 
HIF-1 
regulator 
PHD-1 5’-primer 
3’-primer 
GGCGATCCCGCCGCGC 
CCTGGGTAACACGCC 
PHD2 5’-primer 
3’-primer 
GCACGACACCGGGAAGTT 
CCAGCTTCCCGTTACAGT 
PHD-3 5’-primer 
3’-primer 
ATCGACAGGCTGGTCCTCTA 
CTTGGCATCCCAATTCTTGT 
p300 5’-primer 
3’-primer 
GGAAGTGCTGGCAACTTACTG 
CCATAAGGATTGGGGTTGTTC 
CBP 5’-primer 
3’-primer 
CTGAGACCCTAACGCAGGTTT 
GCTGTCCAAATGGACTTGTGT 
PCAF 5’-primer 
3’-primer 
CTGGAGGCACCATCTCAACGAA 
ACAGTGAAGACCGAGCGAAGCA 
Antioxidant 
enzymes 
SOD1 5’-primer 
3’-primer 
AATGGACCAGTGAAGGTGTGGGG 
CACATTGCCCAAGTCTCCAACATGC 
SOD2 5’-primer 
3’-primer 
ATGTTGAGCCGGGCAGTGTG 
GTGCAGCTGCATGATCTGCG 
GPX1 5’-primer 
3’-primer 
CGGCCCAGTCGGTGTATGC 
CGTGGTGCCTCAGAGGGAC 
Catalase 5’-primer 
3’-primer 
GAACTGTCCCTACCGTGCTCGA 
CCAGAATATTGGATGCTGTGCTCCAGG 
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